Pharmacokinetics of inhaled drugs

British Journal of Clinical Pharmacology

Volumn 42, Issue 6, 1996, Pages 697-705

  Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

inhaled drugs; lung bioavailability; pharmacokinetics

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; SALBUTAMOL; SALBUTAMOL SULFATE;

AREA UNDER THE CURVE; ASTHMA; BIOAVAILABILITY; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

EID: 0029958486     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1996.00493.x     Document Type: Review

References (55)

1. Newnham DM, Wheeldon NM, Lipworth BJ, McDevitt DG. A single-dosing comparison of the relative cardiac beta 1/beta 2 activity of inhaled fenoterol and salbutamol in normal subjects. Thorax 1993; 48: 656-658.
2. 2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose inhaler and modified actuator device. Br J Clin Pharmacol 1993; 36: 445-450.
3. Newnham DM, Lipworth BJ. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (Ventstream). Thorax 1994; 49: 762-770.
4. Clark DJ, Gordon-Smith J, McPhate G, Clark GA, Lipworth BJ. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax 1996; 51: 325-326.
5. Clark DJ, Lipworth BJ. Lung bioavailability of chlorofluorocarbon free, dry-powder and chloroflorocarbon containing formulations of salbutamol. Br J Clin Pharmacol 1996; 41: 247-249.
6. Barry PW, O'Callaghan C. The use of the chlorofluorocarbon free salbutamol preparation, Airomir, with different spacer devices. Thorax 1995; 50(Suppl 2): A78.
7. Clark DJ, Lipworth BJ. Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device. Thorax 1996; (in press).
8. Barry PW, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range. Eur Respir J 1994; 71: 1707-1709.
9. O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of the drug. Thorax 1993; 48: 603-606.
10. O'Callaghan C, Cant M, Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation. Thorax 1994; 49: 961-964.
11. Barry PW, O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the nebuhaler. Br J Clin Pharmacol 1995; 40: 76-78.
12. Borgstrom L, Newman S, Wheis ZA, Moren F. Pulmonary deposition of inhaled terbutaline: comparison of scanning gamma camera and urinary excretion methods. J Pharm Sci 1992; 81: 753-755.
13. Borgstrom L, Derom E, Stahl E, Wahlinboll E, Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996; 153: 1636-1640.
14. Erkstrom T, Andersson AC, Skedinger M, Lindblah C, Stahl E. Dose potency relationship of terbutaline inhaled via Turbuhaler or via pressurised metered dose inhaler. Ann Allergy Asthma Immunol 1995; A: 228-332.
15. Hindle M, Chrystyn H. Determination of relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34: 311-315.
16. Lipworth BJ, Newnham DM, Clark RA, Dhillon DP, Winter JH, McDevitt DG. Comparison of the relative airways and systemic potencies of inhaled fenoterol and salbutamol in asthmatic patients. Thorax 1995; 50: 54-61.
17. Engel T, Scharaling B, Skovsted B, Heinig JH. Effects, side-effects and plasma concentrations of terbutaline in adult asthmatics after inhaling from a dry-powder inhaler device at different inhalation flows and volumes. Br J Clin Pharmacol 1992; 33: 439-444.
18. Hindle M, Newton DAG, Chrystyn H. Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. Thorax 1993; 48: 607-610.
19. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davis P, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl 122): 89-95.
20. Andersson P, Ryrfeldt A. Biotransformation of the topical glucocorticoids, budesonide and beclomethasone, 17,21-diapropionate in human liver and lung homogenate. J Pharm Pharmacol 1984; 36: 763-765.
21. Trescoli-Serrano C, Ward MJ, Rajput R, Garcia-Zorcaco M. Does swallowing charcoal affect gastrointestinal absorption of inhaled beclamethasone. Eur Respir J 1995; 8: S304.
22. Harding SM. The human pharmacology of fluticasone propionate. Resp Med 1990; 84((Suppl A)): 25-29.
23. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from turbuhaler is twice that from a pressurised metered dose inhaler. Eur Respir J 1994; 7: 1839-1844.
24. Pedersen S, Steffensen G, Ekman I, Tonnesson M, Borga O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987; 31: 579-582.
25. Pedersen S, Steffensen G, Ohlsson SV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a turbuhaler. Br J Clin Pharmacol 1993; 36: 211-214.
26. Agertoft L, Pedersen S. Importance of the inhalaton device on the effect of budesonide. Arch Dis of Child 1993; 69: 130-133.
27. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994; 88: 373-381.
28. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994; 149(Suppl): A212.
29. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996; 51: 262-266.
30. Clark DJ, Clark RA, Lipworth BJ. Comparative systemic bioactivity of inhaled budesonide and fluticasone propionate in asthmatic children. Thorax 1996; (in press).
31. Thorsson L, Dahlstrom K, Edsbacker S, Kullen N, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996, (in press).
32. Lonnebo A, Grahnen A, Jansson B, Brundin M, Ling-Andersson A, Eckernass SA. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur J Clin Pharmacol 1996; 49: 456-463.
33. Hogger P, Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.
34. Wurthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wissl 1992; 4: 161-167.
35. Fuller RW, Collier JG. The pharmacokinetic assessment of sodium cromogylcate. J Pharm Pharmacol 1983; 35: 289-292.
36. Neale MG, Brown K, Hodder RW, Auty RM. The Pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. Br J Clin Pharmacol 1986; 22: 373-382.
37. Richards R, Dickson CR, Renwick AG, Lewis RA, Holgate ST. Absorption and disposition kinetics of cromolyn sodium and the influence of inhalation technique. J Pharmacol Exp Ther 1987; 241: 1028-1032.
38. Moss GF, Jones KM, Ritchie JT, Cox JSG. Plasma levels and urinary excretion of disodium cromoglycate after inhalation by human volunteers. Toxicol Appl Pharmacol 1971; 147-156.
39. Benson MK, Curry SH, Mills GGD'A. Hughes DTD. Uptake of disodium cromoglycate in obstructive airways disease. Clin Allergy 1973; 3: 389-394.
40. Auty RM, Brown K, Neale MG, Snashawl PD. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the spinhaler. Br J Dis Chest 1987; 81: 371-380.
41. Richards R, Has A, Simpson SF, Britten A, Renwick AG. Holgate ST. Effect of methacholine induced bronchoconstriction on the pulmonary distribution and plasma pharmacokinetics of inhaled sodium cromoglycate in subjects with normal and hyperreactive airways. Thorax 1988; 43: 611-616.
42. Richards R, Simpson SF, Renwick AG, Holgate ST. Inhalation rate of sodium cromoglycate determines plasma pharmacokinetics and protection against AMP-induced bronchoconstriction in asthma. Eur Respir J 1988; 1: 896-901.
43. Richards R, Fowler C, Simpson S, Renwick AG, Holgate ST. Inhaled histamine increases the rate of absorption of sodium cromoglycate from the lung. Br J Clin Pharmacol 1992; 33: 337-341.
44. Patel KR, Tullett WM, Neale MG, Wall RT, Tan KM. Plasma concentrations of sodium cromoglycate given by nebulisation and metered dose inhalers in patients with exercise-induced asthma: relationship to protective effect. Br J Clin Pharmacol 1986; 21: 231-233.
45. Neale MG, Brown K, Foulds RA, Lal S, Morris DA, Thomas D. The pharmacokinetics of nedocromil sodium a new drug for the treatment of reversible obstructive airways disease in human volunteers and patients with reversible obstructive airways disease. Br J Clin Pharmacol 1987; 24: 493-501.
46. Richards R, Fowler C, Simpson SF, Renwick AG, Holgate ST. Deep inspiration increases the absorption of inhaled sodium cromoglycate. Br J Clin Pharmacol 1989; 27: 861-865.
47. Summers QA, Singh S, Honeywell RG, Renwick AG, Holgate ST. The effect of respiratory manoeuvres and pharmacological agents on the pharmacokinetics of nedocromil sodium after inhalation. Br J Clin Pharmacol 1992; 33: 431-438.
48. Ghosh SK, Neale MG, Patel KR. The effects of physiological manoeuvres on the absorption of inhaled nedocromil sodium. Br J Clin Pharmacol 1994; 37: 305-308.
49. Summers QA, Honeywell R, Renwick AG, Holgate ST. The protective efficacy of inhaled oral and intravenous nedocromil sodium against adenosine-5-monophosphate induced bronchoconstriction in asthmatic volunteers. Pulm Pharmacol 1990; 3: 190-197.
50. Klastersky J, Geuning C, Movawad E, Daneau D. Endotracheal gentamicin in bronchial infections in patients with tracheostomy. Chest 1972; 161: 117-120.
51. Odio W, Van Laer E, Klastersky J. Concentrations of gentamicin in bronchial secretions after intramuscular and endotracheal administration. J Clin Pharmacol 1975; 15: 518-524.
52. Lake KB, Van Dyke JJ, Roumsfeld JE. Combined topical and pulmonary systemic gentamicin: the question of safety. Chest 1975; 68: 62-64.
53. Baran D, Dachy A, Klastersky J. Concentration of gentamicin in bronchial secretions of children with cystic fibrosis or tracheostomy. Int J Clin Pharmacol 1975; 12: 336-341.
54. Mukhopadhyay S, Staddon GE, Eastman C, Palmer M, Rhysdavies E, Carswell F. The quantitative distribution of nebulised antibiotic in the lung and cystic fibrosis. Respir Med 1994; 88: 203-211.
55. Masood AR, Thomas SHL. Systemic absorption and nebulised morphine compared with oral morphine in healthy subjects. Br J Clin Pharmacol 1996; 41: 250-252.